The risk of posterior reversible encephalopathy syndrome (pres) with tyrosine kinase inhibitors: A disproportionality analysis from VigiBase and AERS databases

被引：0
|
作者：
Velez-Nandayapa, Luis [1 ]
Das, Anusmita [2 ]
Saxena, Amit [2 ]
Parulekar, Vishaka [3 ]
Chhabra, Naveen [3 ]
Izquierdo, Miguel [4 ]
De Zeeuw, Pierre [5 ]
Schaart, Edwin [6 ]
Eisinger, Johannes [5 ]
机构：
[1] Univ Basel, Basel, Switzerland
[2] Novartis, Safety Signal Detect MQM, Basel, Switzerland
[3] Novartis, Patient Safety Oncol, Hyderabad, India
[4] Novartis, Clin Dev Oncol, Basel, Switzerland
[5] Novartis, Patient Safety Oncol, Basel, Switzerland
[6] Novartis, Basel, Switzerland
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
924
引用
收藏
页码：425 / 426
页数：2
相关论文
共 49 条
  • [21] Predictors of Posterior Reversible Encephalopathy Syndrome (PRES) in Women With Pre-eclampsia/Eclampsia: A Retrospective Analysis
    Bahadur, Anupama
    Mundhra, Rajlaxmi
    Singh, Rajni
    Mishra, Juhi
    Suresh, Gayatri
    Jaiswal, Shweta
    Sinha, Dibna
    Singh, Mritunjai
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [22] Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase
    Mahe, Julien
    de Campaigno, Emilie Patras
    Chene, Anne-Laure
    Montastruc, Jean-Louis
    Despas, Fabien
    Jolliet, Pascale
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (10) : 2373 - 2383
  • [23] Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes
    Qi Chen
    Xin Zhao
    Hai-Xia Fu
    Yu-Hong Chen
    Yuan-Yuan Zhang
    Jing-Zhi Wang
    Yu Wang
    Feng-Rong Wang
    Xiao-Dong Mo
    Wei Han
    Huan Chen
    Ying-Jun Chang
    Lan-Ping Xu
    Kai-Yan Liu
    Xiao-Jun Huang
    Xiao-Hui Zhang
    Bone Marrow Transplantation, 2020, 55 : 2035 - 2042
  • [24] POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES) IN A PATIENT WITH HIGH RISK NEUROBLASTOMA POST AUTOLOGOUS BONE MARROW TRANSPLANT (BMT)
    Kalra, Manas
    Sabharwal, R. K.
    Yadav, Satya Prakash
    Sachdeva, Anupam
    Radhakrishnan, Nita
    Bhat, Sunil
    Katewa, Satyendra
    Anjan, Madasu
    Kharya, Gaurav
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 838 - 838
  • [25] Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes
    Chen, Qi
    Zhao, Xin
    Fu, Hai-Xia
    Chen, Yu-Hong
    Zhang, Yuan-Yuan
    Wang, Jing-Zhi
    Wang, Yu
    Wang, Feng-Rong
    Mo, Xiao-Dong
    Han, Wei
    Chen, Huan
    Chang, Ying-Jun
    Xu, Lan-Ping
    Liu, Kai-Yan
    Huang, Xiao-Jun
    Zhang, Xiao-Hui
    BONE MARROW TRANSPLANTATION, 2020, 55 (10) : 2035 - 2042
  • [26] PRES-ing for Answers About Long-Term Seizure Risk in Patients With Posterior Reversible Encephalopathy Syndrome
    Spencer, David
    EPILEPSY CURRENTS, 2015, 15 (06) : 317 - 318
  • [27] POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES) IN PATIENTS WITH CKD: AN INSIGHT FROM US NATIONWIDE INPATIENT SAMPLE (NIS)
    He, Mingyue
    Borden, Sean
    Gillespie, Avrum
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S82 - S83
  • [28] Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report
    Patwari, Anannya
    Bhatlapenumarthi, Vineel
    Pascual, Sheila K.
    CASE REPORTS IN ONCOLOGY, 2020, 13 (02): : 1013 - 1019
  • [29] Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
    Shah, Rashmi R.
    DRUG SAFETY, 2017, 40 (05) : 373 - 386
  • [30] Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
    Rashmi R. Shah
    Drug Safety, 2017, 40 : 373 - 386
12345